SI-BONE, Inc.

SIBN

US8257041090

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 16:00:00 2024-07-17 EDT			5-day change	1st Jan Change
17.11 ^USD	+0.82%		+26.27%	-18.48%

07-15	Morgan Stanley Lowers Price Target on SI-Bone to $21 From $25, Keeps Overweight Rating	MT
07-01	SI-BONE, Inc.(NasdaqGM:SIBN) added to Russell Small Cap Comp Value Index	CI

SI-BONE, Inc. Does Not Issue 2021 Financial Guidance due to COVID-19

January 07, 2021 at 07:00 am

SI-BONE, Inc. announced that due to COVID-19 the company is unable to estimate the pandemic’s impact on operations and financial results and is not issuing 2021 financial guidance at this time.

Latest news about SI-BONE, Inc.

Morgan Stanley Lowers Price Target on SI-Bone to $21 From $25, Keeps Overweight Rating	07-15	MT
SI-BONE, Inc.(NasdaqGM:SIBN) added to Russell Small Cap Comp Value Index	06-30	CI
SI-BONE, Inc.(NasdaqGM:SIBN) added to Russell 3000 Value Index	06-30	CI
SI-BONE, Inc.(NasdaqGM:SIBN) added to Russell 2500 Value Index	06-30	CI
SI-BONE, Inc.(NasdaqGM:SIBN) added to Russell 2000 Value Index	06-30	CI
SI-BONE, Inc.(NasdaqGM:SIBN) added to Russell Microcap Value Index	06-30	CI
SI-BONE, Inc.(NasdaqGM:SIBN) added to Russell 3000E Value Index	06-30	CI
Transcript : SI-BONE, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 11:20 AM	05-14
Morgan Stanley Trims Price Target on SI-Bone to $25 From $26, Keeps Overweight Rating	05-07	MT
Transcript : SI-BONE, Inc., Q1 2024 Earnings Call, May 06, 2024	05-06
Earnings Flash (SIBN) SI-BONE Posts Q1 Revenue $37.9M, vs. Street Est of $36.5M	05-06	MT
SI-BONE, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-06	CI
Si-Bone, Inc. Increases Revenue Guidance for 2024	05-06	CI
Piper Sandler Initiates SI-Bone With Overweight Rating, Price Target is $25	03-28	MT
Transcript : SI-BONE, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 08:30 AM	03-12
Morgan Stanley Raises SI-Bone Price Target to $26 From $25, Maintains Overweight Rating	02-27	MT
Truist Securities Adjusts SI-Bone Price Target to $24 From $26, Maintains Buy Rating	02-27	MT
Transcript : SI-BONE, Inc., Q4 2023 Earnings Call, Feb 26, 2024	02-26
Earnings Flash (SIBN) SI-BONE Posts Q4 Revenue $38.9M, vs. Street Est of $38.6M	02-26	MT
SI-BONE, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-26	CI
SI-BONE, Inc. Provides Earnings Guidance for the Year 2024	02-26	CI
Si-bone Insider Sold Shares Worth $808,591, According to a Recent SEC Filing	02-21	MT
SI-Bone Implant Receives Expanded FDA Approval	01-30	MT
SI-Bone Shares Up After Receiving FDA Approval for Expanded Device Use	01-30	DJ
SI-BONE, Inc. Receives FDA 510(k) Clearance for a Smaller Diameter iFuse Bedrock Granite Implant with an Expanded Indication and Application	01-30	CI

SI-BONE, Inc. is a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy. The Company specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The Company's products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The Company's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-08-05 - Q2 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for SI-BONE, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

17.11 USD

Average target price

25.11 USD

Spread / Average Target

+46.76%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Equipment

	1st Jan change	Capi.
SI-BONE, INC.	-18.48%	699M
SHOCKWAVE MEDICAL	+75.69%	12.57B
PENUMBRA, INC.	-19.21%	7.63B
MASIMO CORPORATION	-7.03%	5.84B
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.	+10.32%	5.16B
GETINGE AB	-16.50%	4.75B
ASAHI INTECC CO., LTD.	-12.04%	4.17B
APT MEDICAL INC.	+17.06%	4.16B
INARI MEDICAL, INC.	-9.70%	3.37B
NOVOCURE LIMITED	+28.00%	2.07B

Medical Equipment

SI-BONE, Inc.

Equities

SIBN

US8257041090

Medical Equipment, Supplies & Distribution

SI-BONE, Inc. Does Not Issue 2021 Financial Guidance due to COVID-19

Latest news about SI-BONE, Inc.

Chart SI-BONE, Inc.

Company Profile

Income Statement Evolution

Ratings for SI-BONE, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Medical Equipment